NovaVive Inc. Summarizes Canine Cancer Data Presented at World Veterinary Cancer Congress
The results of clinical studies using MCW formulations in ameliorating neutropenia and inducing serum cytokine synthesis were presented at the 3rd World Veterinary Cancer Congress (WVCC) in May, 2016 in Brazil.
NovaVive Inc. Announces its Canine Cancer Development Plan
Building on its safe and effective treatment for canine mammary cancer (Immunocidin®), NovaVive is targeting canine hemangiosarcoma, chemotherapy-induced neutropenia, and palliation as new indications.
Settle®: A Regulator-Approved Antibiotic Alternative for Treating Equine Endometritis
NovaVive offers an alternative to antibiotics for the treatment of equine endometritis: Settle®. This product is fully approved by regulators in the U.S. and Australia for endometritis caused by Streptococcus zooepidemicus.
U.S. and Canadian Regulator-Approved Immunotherapeutic Available for Equine Sarcoid Tumors
NovaVive's cancer immunotherapy, Immunocidin(R), received USDA and CFIA approval for the treatment of equine sarcoid tumors in February, 2016. The Company believes that this is North America's first approved sarcoid therapy.
Belleville, Ontario – Graeme McRae, Founder and Chairman Emeritus of Bioniche Life Sciences Inc., has founded NovaVive Inc., a Belleville, Ontario, Canada-based company that is acquiring and developing specialty, imm...